Hansen, Mueller Industries director, sells $105,710 in stock
Investing.com - Goldman Sachs has reiterated its Buy rating and $8.00 price target on Gossamer Bio Inc. (NASDAQ:GOSS), currently trading at $2.78, following a 7.0% drop in the company’s stock price. Despite recent volatility, the stock has surged over 200% year-to-date, though InvestingPro analysis suggests the stock is currently overvalued.
The stock underperformed compared to the broader XBI index, which fell 1.6%, after Gossamer announced an option agreement to potentially acquire privately-held Respira Therapeutics. According to InvestingPro data, analyst consensus remains bullish with price targets ranging from $6 to $15, though the company faces challenges with rapid cash burn and negative earnings.
Respira’s leading pipeline candidate is RT234, an inhaled vardenafil dry powder therapy being investigated as an on-demand treatment for pulmonary hypertension.
Goldman Sachs views RT234 as "clinically derisked" since vardenafil is already approved, though with a different delivery mechanism in this formulation.
The investment bank notes investors will likely seek evidence on RT234’s differentiation, clarity on trial design for an on-demand pulmonary arterial hypertension treatment, and how it fits into the treatment landscape alongside existing options.
In other recent news, Gossamer Bio, Inc. has entered into an Option Agreement and Plan of Merger and Reorganization with Prana Bio, Inc., the owner of Respira Therapeutics, Inc. This agreement gives Gossamer Bio the right to acquire Respira Therapeutics through a merger with Prana Bio, with the option available until December 31, 2027, or upon the completion of certain development activities. As part of this deal, Gossamer Bio will issue 2.5 million shares of common stock at signing, with an additional 1.5 million shares to be issued if the acquisition option is exercised. The agreement also includes milestone payments and royalties on potential sales of Respira’s lead product, RT234. Meanwhile, H.C. Wainwright has maintained its Buy rating for Gossamer Bio, setting a $10 price target, following the firm’s 27th Annual Global Investment Conference. Cantor Fitzgerald also reiterated its Overweight rating on the company, highlighting positive investor sentiment as the company approaches its PROSERA clinical trial readout in February 2026. These developments underscore Gossamer Bio’s strategic moves and ongoing efforts in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.